Botanix (ASX:BOT) Is Bleeding Cash, Can Sofdra Save It?

Botanix Pharmaceuticals is the definition of a high-risk, high-reward stock.

It has been a year of heavy operating cash burn, driven by a 50-person sales force and high API costs. With the stock down 80% from its highs, investors are now asking the key question: can Botanix actually pull off a turnaround?

The company is spending heavily to market and distribute Sofdra. We can see that clearly in the numbers, with Botanix reporting A$24M in product sales and marketing costs in H1 FY26 alone, up 179%, reflecting the buildout of its 50-person sales team. At 150% of net revenue, that looks alarming in isolation, but for a US biotech in its commercial launch year, it is not unusual.

From here, Botanix needs to focus on cash discipline, particularly through reducing API costs. Management is targeting a 25% to 40% improvement in cost of goods sold as it negotiates with suppliers. If successful, that could lift gross margins from 64% to around 75% to 80%, potentially adding A$3M to A$5M in gross profit.

That is the key milestone. After a large capital raise at a significant discount, existing investors were heavily diluted, which showed just how urgently Botanix needed cash to fund growth. That remains the core concern. After shareholders have already taken that hit, the question now is whether Botanix can make it through the next year and prove the model works.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

Physician Satisfaction and Platform Differentiation

It is not all negative for Botanix. Market research from 30 US dermatology HCPs showed that 90% expect to increase Sofdra prescribing over the next six months, while no respondents expected prescribing to decline. That is a strong signal that prescription volumes could continue building through H2 FY26.

The SendRx direct-to-patient fulfilment platform may also be one of Botanix’s most underappreciated assets. It delivers fill rates 2.5x above the industry standard, with 96% of surveyed physicians rating it favourably and 67% rating it very favourably. On top of that, 72% said patients preferred home delivery.

That matters because SendRx does more than improve convenience. By bypassing the wholesaler, Botanix is able to capture a larger share of gross revenue per script, which could become increasingly valuable as prescription volumes scale.

Levers That Could Materially Change the Investment Thesis

What will really drive more value for Botanix is revenue scale. The company needs to grow revenue meaningfully to absorb the large upfront launch costs and ongoing overhead tied to Sofdra.

One of the most important metrics here is GTN yield, which currently sits at 24%. That means for every dollar of Sofdra revenue generated, Botanix is keeping 24 cents. Management’s target is to lift that to 30% to 40%. A low GTN yield early in a launch is not unusual in biotech, as companies often trade away economics at the start to build momentum. But from here, investors will want to see that yield improve steadily toward the target range.

We have already covered the API cost reduction story, so the other key lever is the broader value of the SendRx platform. This is an early moat for Botanix. It gives the company a scalable distribution network that can fulfil orders quickly without relying as heavily on third-party channels that can pressure margins.

That becomes even more important if Botanix launches more products over time. A broader product base would allow the company to spread the fixed cost of its 50-person sales team across a larger revenue base. Given sales and marketing is currently the main driver of losses, the operating leverage from that could be significant.

Is Botanix worth the investment?

The key takeaway for investors is that after an 80% drawdown, the risk-reward looks a lot better than it did before. But Botanix is still far from risk free.

There is still a scenario, even if it is lower probability, where the company runs into serious funding pressure if we do not see a material turnaround in revenue. That risk has not disappeared.

At the same time, revenue is expected to improve sharply and prescription shipments are ramping quickly. That creates the potential for meaningful upside if execution stays strong.

Price targets around 40 cents imply material upside from here, but that outcome depends on Botanix delivering strong growth and much better execution over the next 12 months. For us, the main point is that a lot of the major risk now appears to be priced in, but the company still has to prove the turnaround.